INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of “Hold” from Analysts

Shares of INmune Bio, Inc. (NASDAQ:INMB) have earned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $18.00.

Several research analysts have weighed in on INMB shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of INmune Bio in a report on Wednesday, October 8th. Wall Street Zen lowered INmune Bio from a “hold” rating to a “sell” rating in a report on Saturday, August 2nd.

INmune Bio Stock Up 5.8%

NASDAQ:INMB opened at $1.83 on Monday. The stock’s fifty day simple moving average is $1.95 and its 200-day simple moving average is $4.11. The firm has a market capitalization of $48.64 million, a P/E ratio of -0.86 and a beta of 0.95. INmune Bio has a 12-month low of $1.71 and a 12-month high of $11.64.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, October 30th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.07. As a group, equities research analysts expect that INmune Bio will post -2.24 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INMB. Rhumbline Advisers lifted its holdings in shares of INmune Bio by 14.4% in the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock valued at $150,000 after purchasing an additional 2,409 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of INmune Bio by 9.0% in the first quarter. Bank of New York Mellon Corp now owns 54,923 shares of the company’s stock valued at $429,000 after purchasing an additional 4,521 shares in the last quarter. MAI Capital Management lifted its holdings in shares of INmune Bio by 6.0% in the first quarter. MAI Capital Management now owns 106,797 shares of the company’s stock valued at $834,000 after purchasing an additional 6,030 shares in the last quarter. Quarry LP bought a new stake in shares of INmune Bio in the first quarter valued at about $48,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of INmune Bio by 19.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 41,320 shares of the company’s stock valued at $323,000 after purchasing an additional 6,654 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.